Breaking news

How AI Is Shaping The Future Of The Middle East

The Middle East is undergoing a major transformation driven by Artificial Intelligence (AI). What once seemed like a futuristic concept is now a powerful force reshaping economies, industries, and daily life. As AI accelerates across the region, its potential to reshape sectors is becoming increasingly apparent.

IDC forecasts AI spending in the Middle East and Africa (MEA) to grow at an impressive compound annual growth rate of 29.7%, with the region expected to reach $6.4 billion by 2026. McKinsey’s estimates suggest AI could generate up to $150 billion in value for GCC countries, contributing more than 9% to their GDPs.

To seize this opportunity, organizations across the region must act now, embracing AI and incorporating it into their operations to stay competitive and drive future growth.

A Region Ready For Change

Across the Middle East, governments are incorporating AI into their national strategies. The UAE, for instance, is a leader in AI adoption, with initiatives like the UAE National AI Strategy 2031 and Abu Dhabi’s Advanced Technology Research Council (ATRC) pushing AI research and innovation. These initiatives aim to make the UAE the world’s first fully AI-native government.

Saudi Arabia’s Vision 2030 and various AI projects in Abu Dhabi and Dubai are also redefining urban infrastructure and service delivery. These include autonomous transportation programs and AI-driven healthcare solutions. Such projects are transforming cities, making them smarter, more efficient, and more sustainable.

Transformative Potential For Organizations

AI’s real impact lies in its practical applications. For example, AI is being integrated into government services to enhance efficiency and improve customer experiences, transforming both public and private sector operations.

In addition, AI is helping various industries optimize their operations and customer engagement. With AI tools like chatbots, predictive analytics, and data-driven decision-making, companies are improving efficiency and driving new forms of value across sectors.

Overcoming Barriers To AI Adoption

Despite its promise, AI adoption presents several challenges. Organizations in the region often struggle with outdated infrastructure, inconsistent data, and a shortage of skilled AI professionals. To overcome these obstacles, businesses must invest in robust digital infrastructure and scalable AI solutions.

There is also a significant talent gap in the Middle East when it comes to AI. This underscores the importance of investing in education and training programs to cultivate local expertise and drive long-term innovation.

Moreover, data governance is key to ensuring that AI models work effectively. Proper data management is necessary to produce reliable, accurate results from AI systems.

Looking To The Future

As AI continues to advance, it is expected to become even more integrated into the region’s daily life over the next five years. Companies must align their AI strategies with their business goals to ensure sustainability and long-term success.

The Middle East is well-positioned to become a global leader in AI, with the UAE leading the charge. However, this requires collaboration among governments, businesses, and tech providers to foster inclusive growth that benefits all sectors.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

The Future Forbes Realty Global Properties
Aretilaw firm
Uol
eCredo

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter